Earnings call transcript: Mega Lifesciences Q4 2025 reports steady growth amid currency challenges

Mega Lifesciences reported Q4 2025 EPS of 0.66, meeting analyst expectations, with revenue of THB 3.66 billion (reported +0.2% YOY; normalized +9.3% YOY). FY2025 highlights include improved gross margin to 52.2% (from 50.5%), EBITDA of THB 2.74 billion (+2.6% YOY), and maintained dividend policy (THB 1.6); management outlined THB 2.7 billion capex over the next ~3 years to expand manufacturing. The stock fell ~5.19% intraday to $11.70 despite operational recovery momentum and normalization-adjusted growth; primary near-term risks are currency appreciation (THB vs USD), Myanmar market access, and higher taxes.

Analysis

Management’s playbook is pivoting the company from an import-reliant distributor to a multi-jurisdictional manufacturer, which materially changes where margin risk sits. Localized production shortens lead times, raises tender competitiveness and converts FX volatility from an earnings headwind into a controllable input-cost variable over a 12–36 month horizon.

Myanmar is the primary demand swing-factor and will remain lumpy: licencing cadence and public-sector tendering create episodic revenue spikes rather than smooth growth. That means near-term quarter-to-quarter volatility is structural, not cyclical — catalysts that prove sustained license liberalization or on-the-ground purchasing-power recovery will compress perceived political risk and re-rate peers exposed to the market.

Tax and reported-currency distortions have masked free-cash-flow strength; operating cash conversion is the practical cushion for aggressive CapEx but execution risk is real. Watch two execution vectors as binary catalysts: (1) commissioning milestones in Southeast Asian plants and (2) progress on the GLP‑1/semaglutide licensing and registrations — each can drive a revaluation over 6–18 months if paired with stable FX.

Consensus is underestimating the optionality from manufacturing rollout and pipeline licensing while overweighting headline-reported volatility. The sell reaction gives an asymmetric entry for patient capital: the path to improved unit economics is visible and milestone-driven, so position sizing should be milestone-tethered rather than time-only based.

Key Decisions for Investors

• Buy MEGA (SET:MEGA) — build a 2% NAV long over the next 2 sessions on any weakness. Timeframe 6–12 months; target +25% on successful commissioning/licensing momentum; hard stop -12% if either (a) a plant commissioning slips >6 months or (b) Myanmar imposes new distributor restrictions. Rationale: captures branded-margin upside while keeping position tied to execution milestones.
• Buy longer-dated call option on MEGA (9–18 months tenor) — allocate 0.5% NAV to calls to express asymmetric upside into GLP‑1 licensing and capacity ramp milestones. Payoff: 2x–4x on successful regulatory/market wins; downside limited to premium. Use options to isolate catalyst risk without enlarging equity exposure.
• Hedge translation/Fx risk — enter USD/THB forward or option to neutralize ~60% of anticipated translation volatility on the MEGA exposure for 6–12 months (ticker: USD/THB). Cost vs reward: modest premium paid to remove headline-reporting noise; unwind if on-the-ground data confirms persistent improvements in local demand or if THB moves >3% against view.